

LUDLOW RESEARCH

MARKET RESEARCH REPORT

PHONE: (347) 483-0121
 EMAIL: INFO@LUDLOWRESEARCH.COM

AURIS MEDICAL HOLDING (NASDAQ: EARS)



Last Updated: Oct. 18, 2018

Ludlow Research Issues Trader Alert on EARS Based on Technical Indicator

EARS Fills Daily Chart Gap to Offer More Attractive Trading Opportunity Below \$1.00

(NEW YORK) – Ludlow Research has issued an alert on **Auris Medical Holding** (NASDAQ: [EARS](#)), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurology and mental disorders supportive care, with an attractive technical analysis opportunity below \$1.00 per share.

Report Summary

EARS recent run from around \$0.30 to a high of \$2.00 in just the month of October had pushed the stock into highly over bought territory, with an RSI approaching 90. In addition, EARS had found resistance at its 200-day moving average during this run, which is now around \$1.50 per share.

More important, EARS had formed a “gap” in its daily trading chart between \$1.00 to \$1.25, which historically needs to be ‘refilled’ before most stocks can continue any next leg upwards.

Based on these indicators EARS was obviously positioned for a pullback after such a strong run. But with the RSI pulling back, and price now refilling the gap in daily chart, Ludlow Research feels anything below \$1.00 to be a much more attractive trading opportunity for anyone looking to take an entry position in this stock.

REGISTER FOR UPDATES

To receive updates on this company report, or on new exclusive investment opportunities, please register to Ludlow Research Investor Mailing list at <https://ludlowresearch.com/investors>

Phase 3 Hearing Loss Product (AM-111)

Auris Medical has two Phase 3 programs under development: AM-111 for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. In August 2018, the company announced feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA) related to the development plan and regulatory pathway for AM-111, its investigational treatment for sudden sensorineural hearing loss.

The FDA reviewed the Company's proposed concept for a placebo-controlled pivotal trial with AM-111 0.4 mg/mL in patients suffering from acute profound hearing loss. The trial protocol builds to a large extent on the design and outcomes from HEALOS and also incorporates specific feedback provided by the European Medicines Agency (EMA) earlier this year. In a written response the FDA endorsed the proposed choice of primary and secondary efficacy endpoints, the safety endpoints, as well as the planned sample size and statistical methodology. In addition, the FDA provided important guidance on the regulatory path forward.

About AM-111

AM-111 is being developed in a biocompatible gel formulation for the treatment of sudden sensorineural hearing loss with a single-dose administration into the middle ear. Its active substance is brimapitide (also known as D-JNKI-1, D-stereoisomer of c-Jun N-terminal Kinase Inhibitor 1), a cell-penetrating peptide which inhibits the JNK stress kinase. JNK is activated following various types of cochlear insults (stress) that cause acute inner ear hearing loss and plays a key role in apoptosis of sensory cells as well as in inflammatory responses. By blocking JNK, AM-111 protects stress-injured cochlear cells and helps to prevent or reduce chronic hearing loss. AM-111's otoprotective effects have been demonstrated in various animal models of cochlear stress, including acute acoustic trauma, acute labyrinthitis (inflammation), drug ototoxicity (aminoglycosides), bacterial infection, cochlear ischemia and cochlear implantation trauma. AM-111 has orphan drug designation from both the US Food and Drug Administration and the European Medicines Agency, and it was granted Fast Track status by the FDA.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1. In addition Auris Medical has two Phase 3 programs under development: AM-111 for sudden sensorineural hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Capital Market under the symbol "EARS."

About Ludlow Research

Ludlow Research is a New York based equity research firm that focuses on providing research coverage and investor awareness services to emerging small-cap companies. For over 14 years we have worked to provide our readers with a simple way of evaluating the current and potential value of small-cap companies, while garnering these clients greater market awareness to new investors. For more information on us please visit www.ludlowresearch.com

Contact:

Ludlow Research

Phone: (347) 483-0121

Email: info@ludlowresearch.com

Disclaimer:

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow Capital, Inc ("Ludlow") does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow was not compensated for this alert. Ludlow, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. (at the time of this alert neither Ludlow, or any of its affiliates held positions in above mentioned securities) These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.

Safe Harbor Statements:

This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Forward-Looking Statements

This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

High Risk

Small and Micro cap, or 'penny stocks', involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.